{"name":"Vaccinex Inc.","slug":"vaccinex-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNcWFNQ0pSdUxxcDZJenJ6TVZNY2tCYmZjTG8ybXJ4Z3NQYUF4ekRIMzFEeEp2aERTTXJVZTFRb3B5eTdOanY5NWlpa3loX21ZenRVcTNHTmxZWUhMa3p3VGtfYll0M01ua0RmVF9PYnBSaU9TYVozNjVPeTN2VUViNXJuSGNiRlZpdHJsb0ZWZVZaUzIyYS1wVWx2VmQydFZKbXdoX0loSmpHNnFDdWRmbA?oc=5","date":"2026-04-05","type":"pipeline","source":"The Chronicle-Journal","summary":"Vaccinex, Inc. - Common Stock (NQ: VCNX - The Chronicle-Journal","headline":"Vaccinex, Inc. - Common Stock (NQ: VCNX - The Chronicle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxOeHliYlFudThqcnhPN2I0VnNFT1MtbDNFRHl6X3VDTUMxZVgyV3ZORG1UdlNVYkRqd2ZNRVhDTjFzWWkwUzRIZlltSUtUTVhRRTdPRUFsY2l5N1pESkgwQVQ4dGVYZXpmRlFvNjRRd3BJdXg5ekt4ZkgzRmktNVJ6aU0zMURfdk9iZDdkV1NTR0tQd1dIeGE0RDM2dzB2M1NKSmVaSkM4U2NjVmZvcmZITS1qUXAtdi0zcnpZSHZfU0ZMZnBiS09Jai1MeDAxcUF5WElEcnRKMjR3a0lOQ1pVQ2xNS29EbVZPSGFTazJXWmtlWnVfS09QdmhCMktRRjV6?oc=5","date":"2025-09-05","type":"pipeline","source":"PR Newswire","summary":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxPeUx4N1VxLVVxc28zWUFqN2xxa0gwU2xfY2FldkpYcDBDNmFxR2V0azFwVXhGN0dNZFJTd3ZXVzU4cHYtbzZHUmNxVUhKandmdlhuOXM1UHRPbTV6VUs0NEt3WnlSYkZib2JaYTcwM1dOTmlSRzJId0E4bXF1M1FCcmJ6QzFQQ0VtZFVkWGN5aGM0X0FmY1RtQWEzZlNqWWtFQ0pmUHZvNU9SV3Q5LUdiekNaZmo0U2xZNkROM2lMQ05MM1REWkMtLUlYVDg3a29idE4zU3NPekFLRHJUeTZNRzhSSFkzQUhfV0VVbWRTcEtFclpHcUxVYXdXT2JINkhubFBNSzlJSldFMHEyLTliclQwTGpyVlNEWG5XRzdR?oc=5","date":"2025-08-12","type":"trial","source":"globenewswire.com","summary":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - globenewswire.com","headline":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPS2hUUU1pbHcwUEUtVFlnY3liNjM4NTFXZldEWThfY2FjWllwY0MyZm15eFhBbEJvdlkwMlh2MkZKc3pqWEhlNzR3ZVQxNS03WnZKSlpkWnpEQlV5UmYzdXZVVFlQRnMwRUFteDZ5ZWQ1SFpsZ05DVVllX0xld2Z0YUFQZnd3MW1GU2dpNWNRY3g4UHYtSHdCalNReVZtVlJ6RnNacXV1emUtWWxWU3pLaG1RdFFkSDF0LXk5T3Nndw?oc=5","date":"2025-07-23","type":"pipeline","source":"AFL-CIO","summary":"Highest-Paid CEOs - AFL-CIO","headline":"Highest-Paid CEOs - AFL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPd3QyQ0JRbGF1TWJBNGZBTXJRWnV1a1hHVGgwcG5DUUFfMmZGYmlYQnpab3ZBVDhkQlU4cVpOdzZpcHd6NWFPbHhJMkkwcGtDbmQ3c0xUSk1kX055NXN1QzNvbzI3Um1BQ3U2WVlWWWtWUzRZWlBob09CdENuZm4zcGRQdThqbFRZNFNBeXBldVpNZTdWMl9tMmRiMHpHMFA4NnZWblRQTVJVMXhScjRjUXVuUmdBYjFBcDA3djNOaXJ5emNId29xN21VRE16SVk0RDhWcFNfR2NQV3pDUy1fLXBWLWZMRFYyOHYxYzJpa1VEWUtlRVpPNUdSRUxraUZESzhPWEZPdHVCNFRLVTdSbG9icUJaQWhyS050WjNzckRFaWpIYWF3cjVUWjQ4dkZUYTlCRlBadjNadHl4OXJtLXQ5dDJnVmc2?oc=5","date":"2025-07-08","type":"pipeline","source":"globenewswire.com","summary":"Alzheimer’s Therapeutics Market on Upward Trajectory Across - globenewswire.com","headline":"Alzheimer’s Therapeutics Market on Upward Trajectory Across","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbnhqY1c5NDBrSlpXSFlXZWhtTHQtcndBN3gtX3MzbEZUN2RzaXpTd190QjdmYjhDQmdBbkUwcGZYZlpjdmZaTWtuRnBMX1J6ODVFWEZ6QnZMVy1PVG9ScUJCN3M2emh1Zlhxek1PQnJ1X3F5NlBXbDRFQVN6ZjBKS3BDOHJDR3BseEFqOUo0UXB6MzZyLTRsc3ZPS2pvZlF3aWYwWnZRRi04ejFMalNWaUp6U19mWnRj?oc=5","date":"2025-05-27","type":"pipeline","source":"neurologyadvisor.com","summary":"Diagnosis and Treatment Strategies for Early Alzheimer Disease: Highlights From AAN 2025 - neurologyadvisor.com","headline":"Diagnosis and Treatment Strategies for Early Alzheimer Disease: Highlights From AAN 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZTlxZ040MTlfbGZwbjduSVY5UnBtbUZ3M3NMMWt1Yzc5S3czN1ZNMmc1MzF3a2lDUFA3dG42WHY1RzhGbzU3bktmZVRwNV9JLUxKcVU1cjJZd19pU2QzZndEbWw1WGowd2dTcGlnc041MzRJT0MxSmpLVW9lT2thcFgxbDczWEpzZEFnOWxYUzJTanZmTUVkMGhzNVZYNFJnV0Y4OEpjZ0w5YUZJYWc?oc=5","date":"2025-03-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology","headline":"Vaccinex plans Nasdaq exit as Alzheimer market pressure grows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOVFY4WXlXMU1vTUFuYXZzYzg1OTVTSEJuZDJSRWVPR0gxZzdQOWhKT3FTTU1xVVIzeXlaRm92eUl6Z0RvOFFMaGswOHprNDgzRzZkTWF0T1dzWEg1c2pqeWdXTlVSNFNMWFctNXR3RVEwd0RSWS1IQk1YVEhYQlNlME9LZTVsX1NhNFJUYjFCM1N4dXFpcUpRSFFqSENVZzNHSktvb2VFX2dFZjVnaHFoLTZvcFFrYmdmdHc?oc=5","date":"2024-06-06","type":"regulatory","source":"Stock Titan","summary":"Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease - Stock Titan","headline":"Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOMGxKQUt2bkFpcGw4LWc4VU9zdTU2cU9tVGxOTTAyVUhjMk41Tnk3ZTV1VnpFalg0YVZLRlRCZDhqalBZNWE4a200MnlSZEFOMDJhaUlTODQyN0hUV1ZuYUI4UXhlY1Z2VE04ME9nQTVtVElqeTRHN01QekVlVE14bmR0OHNMaC1KZE12eQ?oc=5","date":"2024-02-12","type":"deal","source":"finance.yahoo.com","summary":"Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc - finance.yahoo.com","headline":"Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPT05lU2RmbFVLVU92dk9HaHIxaVZDa1BxU3AxLVZ4bjY5aFVJTTR1UXJ1TGsxeU9Pa2Z5eHhjck14UXFhZWlnaEdSTXdtemhlWXhpaVdSSFFicXhfeVVpcHZtVEtWUlZEbGlld3V1d2NBVTNFeDZuN1Jxa3pYVUNFSTEwdy1hM0pxZlduOEtzRy01Z1FlcXR2TXBNMGxfejlTb0hnd0hNU052X3VyYUswTkF1bXZwRDQ?oc=5","date":"2024-01-05","type":"pipeline","source":"Healio","summary":"Survey: Halting neurodegeneration chief concern in Huntington’s disease - Healio","headline":"Survey: Halting neurodegeneration chief concern in Huntington’s disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOSWNUS2xBMzZNRDVEVlhjOGxBbkZtT0l6RmFwWVNKTl9lX0Q1TlpfSFZmRXB3bjFrazNudTFFa3kzTk1IUXQ5ZnhPSTFJU0VpR3N5R1p1NkN0WDFLdnVNdTRmaUNYeTBVTzFGQlA4Nmw5STdGM29rckdqWDRYSlhRYmhoZVpzQlZ3dVpEeE0xUktjXzQ?oc=5","date":"2022-11-11","type":"pipeline","source":"Allied Market Research","summary":"Huntington’s Disease Treatment Market Size, Share | Report - 2031 - Allied Market Research","headline":"Huntington’s Disease Treatment Market Size, Share | Report - 2031","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}